Korea Biomedical Review

[Interview] Rybrevant expands first-line options in EGFR-mutated lung cancer, but cost limits access in Korea

Korea has approved new combinations using Johnson & Johnson (J&J) Innovative Medicine’s Rybrevant (amivantamab), expanding ...